CMBA
TSVT

C.M. Bidwell & Associates’s 2seventy bio TSVT Stock Holding History

C.M. Bidwell & Associates’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-86
Closed -$406 – 536
2024
Q3 		$406 Buy
+86
New +$388 ﹤0.01% 477
2022
Q3 		– Sell
-6,395
Closed -$84K – 540
2022
Q2 		$84K Hold
6,395
– – 0.07% 236
2022
Q1 		$109K Buy
+6,395
New +$108K 0.07% 229

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

C.M. Bidwell & Associates's TSVT Position: Q4 2024 in Review

C.M. Bidwell & Associates sold out of 2seventy bio (TSVT) in Q4 2024, closing a stake of 86 shares — an estimated $406 sold.

C.M. Bidwell & Associates first reported a position in TSVT in Q1 2022 and held it in 3 quarters. The position peaked at $109K in Q1 2022. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2024.

  • C.M. Bidwell & Associates reported no remaining 2seventy bio position as of Q4 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 86 2seventy bio shares in Q4 2024, an estimated $406.
  • C.M. Bidwell & Associates first reported a position in 2seventy bio in Q1 2022 and held it in 3 quarters.
  • C.M. Bidwell & Associates's 2seventy bio position peaked at $109K in Q1 2022.
  • 116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.